Imidazoline receptor 1 (I1R) (I1R)

The Imidazoline receptor 1 (I1R) is a specialized signaling protein, predominantly identified as Nischarin (NISCH), that plays a pivotal role in the central regulation of blood pressure [1][3]. It is localized primarily within the rostral ventrolateral medulla (RVLM) of the brainstem, as well as in the kidneys and pancreatic islets [1]. Activation of the I1R suppresses sympathetic nervous system activity, which facilitates systemic vasodilation and a reduction in arterial blood pressure [2]. Unlike first-generation centrally acting antihypertensives that target alpha-2 adrenergic receptors, selective I1R agonists like moxonidine and rilmenidine offer effective blood pressure control with a significantly reduced incidence of sedative side effects and dry mouth [2][4]. Beyond cardiovascular homeostasis, the Imidazoline receptor 1 is involved in metabolic regulation, where it helps modulate insulin secretion and improve glucose tolerance, making it a target of interest for metabolic syndrome and type 2 diabetes [4][5]. The molecular signaling of I1R is distinct from traditional G protein-coupled receptors, utilizing pathways such as phosphatidylcholine-selective phospholipase C (PC-PLC) and the extracellular signal-regulated kinase (ERK) to exert its physiological effects [3][5]. Current therapeutic applications focus on hypertension management, while ongoing research investigates its potential neuroprotective and anti-inflammatory properties [1][4]. Sources: [1] Head, G. A., & Mayorov, D. N. (2006). Cardiovascular & Hematological Agents in Medicinal Chemistry. [2] Bousquet, P., et al. (2000). American Journal of Hypertension. [3] Piletz, J. E., et al. (2000). Journal of Pharmacology and Experimental Therapeutics. [4] Edwards, L. P., et al. (2001). Journal of Hypertension. [5] UniProt Consortium, Protein Q9Y2I1 (NISCH_HUMAN).

Other names

I1 imidazoline receptorNischarinNISCHI1-receptorImidazoline receptor subtype 1

Activation of I1 receptors in the rostral ventrolateral medulla (RVLM) of the brainstem leads to a decrease in sympathetic nervous system outflow, resulting in reduced peripheral vascular resistance and lower blood pressure.